Related Experiment Videos
[Telematic multicenter study of Pragmarel 100 mg (trazodone)]
L'Encephale
|October 1, 1986
Summary
Trazodone, an antidepressant, demonstrated significant efficacy and safety in a large outpatient study. Pragmarel (trazodone) showed positive results in 82% of patients with various depression types.
Area of Science:
- Psychiatry
- Pharmacology
Context:
- Trazodone is a widely recognized antidepressant with a favorable safety profile.
- Outpatient treatment of depression requires effective and well-tolerated therapeutic options.
Purpose:
- To evaluate the efficacy and safety of Pragmarel (trazodone) in a large, real-world outpatient setting.
- To assess trazodone's effectiveness across different subtypes of depression.
Summary:
- A national study followed nearly 2,000 outpatients treated with Pragmarel 100 mg for four weeks.
- Computerized DSM III criteria identified major affective disorders and other affective disorders.
- 82% of patients experienced good to very good outcomes, with 65% showing over 50% reduction in MADRS scores.
Impact:
- Confirms trazodone's therapeutic value in diverse depressive conditions.
- Highlights Pragmarel's low incidence of side effects and excellent patient acceptability.
- Supports trazodone's established role in managing depression based on extensive clinical data.